In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- A Novel In Vitro Glycosylation Approach For Difficult PTMs
- Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
- Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
GUEST COLUMNISTS
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
-
MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.
-
A Novel In Vitro Glycosylation Approach For Difficult PTMs
Post-translational modifications of membrane proteins have been historically challenging. Research shows how an in vitro approach brings stability and predictability.
-
Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
Risk and fitness for use of interchangeable single-use parts were key themes at the conference. The event exposed communication gaps between suppliers and end-users.
-
Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing
Cell-free expression systems confound the moment of peak expression. These nanosensors signal through crude lysate for process optimization and endpoint monitoring.
-
A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
Fill/finish operations are famously resource-heavy. Nonetheless, Novo set out to achieve ambitious environmental goals with its $4.1 billion project in North Carolina.
-
The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
The Trump administration has effectively merged national security, trade policy, and drug quality. Now, foreign manufacturers lacking deals face paying a "quality tax."
BIOSIMILAR WHITE PAPERS
-
Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing
Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
-
Regulatory Considerations For Excipients Used In Lipid Nanoparticles8/15/2024
Review the regulatory classification of LNPs, liposomes, and novel excipients as well as specific requirements outlined in regulatory guidance documents and strategies to navigate emerging challenges.
-
Considerations For Developing The Recirculation/Perfusion Process6/6/2024
Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation9/1/2025
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Establishing Commercial Manufacturing Services For ADCs6/3/2024
Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.
BIOSIMILAR APP NOTES & CASE STUDIES
- Media And Buffer Mixing Using The Xcellerex™ Magnetic Mixer
- Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals
- Assessing Particle Generation In A Single-Use Mixing System
- A Sustainable Future: Phasing Out Animal Testing
- How To Successfully Isolate Your T Cells
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Sandoz Confirms European Commission Approval For Ranluspec (ranibizumab), Further Strengthening Overall Biosimilars Leadership And Position In Ophthalmology
- Lupin Receives European Commission Approval For Biosimilar Ranibizumab
- Dr. Reddy's Announces USFDA Acceptance To Review Its Biologics License Application (BLA) For Proposed Interchangeable Biosimilar, Abatacept
- Zydus Launches Biosimilar Aflibercept 2 mg ANYRA For Advancing Ophthalmic Care
- Sandoz Receives US FDA Approval To Expand Enzeevu (aflibercept-abzv) Label For Multiple Retinal Indications
- FDA Approves FILKRI7™ (filgrastim-laha), Accord BioPharma's Biosimilar To NEUPOGEN® (filgrastim)
- U.S. FDA Clears IND For Phase 1 Study Of Henlius' Subcutaneous Daratumumab Biosimilar
- STADA And Bio-Thera Receive European Marketing Authorization For Gotenfia, A Biosimilar To Simponi
NEWSLETTER ARCHIVE
- 02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 02.12.26 -- Building Enterprise Resilience From QRM Signals
- 01.29.26 -- The Latest In Upstream HCP Mitigation
- 01.15.26 -- SUS Insufficient For 40% Of Biopharma
- 01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance